GATAD2A: A Potential Drug Target and Biomarker (G54815)
GATAD2A: A Potential Drug Target and Biomarker
GATA/DNA-binding proteins are a family of transcription factors that regulate gene expression by binding to specific DNA sequences. GATAD2A, a member of this family, has been identified as a potential drug target and biomarker for several diseases. In this article, we will discuss the biology of GATAD2A, its potential as a drug target, and its potential as a biomarker for disease.
GATAD2A: Structure and Function
GATAD2A is a 21-kDa protein that contains a N-terminal transmembrane domain, a N-terminal intracellular domain, and a C-terminal T-cell factor-4 (TCF-4) domain. The N-terminal transmembrane domain is responsible for the protein's ability to interact with DNA and the N-terminal intracellular domain is responsible for its ability to interact with the cytoplasmic environment. The C-terminal TCF-4 domain is a protein-coding domain that contains several coiled regions that are involved in protein-protein interactions and may be involved in the regulation of gene expression.
GATAD2A has been shown to play a role in several cellular processes, including cell growth, differentiation, and the regulation of cell-cycle progression. GATAD2A has been shown to promote the G1 phase of the cell cycle and to inhibit the S-phase. This means that GATAD2A is involved in the regulation of the length of the S-phase, which is the stage of the cell cycle where DNA replication occurs.
In addition to its role in cell-cycle regulation, GATAD2A has also been shown to play a role in the regulation of gene expression. GATAD2A has been shown to interact with several transcription factors, including NF-kappa-B, AP-1, and STAT3. This means that GATAD2A is involved in the regulation of gene expression by these transcription factors.
GATAD2A as a Drug Target
GATAD2A has been identified as a potential drug target due to its involvement in several diseases. One of the main reasons for its potential as a drug target is its involvement in cancer. GATAD2A has been shown to promote the growth and survival of several types of cancer, including breast, ovarian, and prostate cancer.
In addition to its role in cancer, GATAD2A has also been shown to be involved in the regulation of stem cell proliferation. GATAD2A has been shown to promote the proliferation of stem cells and to inhibit their differentiation. This means that GATAD2A is involved in the regulation of stem cell biology and has the potential as a therapeutic target for diseases that involve stem cell dysfunction, such as cancer andAuthored by: Ashish Naaz
GATAD2A as a Biomarker
GATAD2A has also been identified as a potential biomarker for several diseases. One of the main reasons for its potential as a biomarker is its involvement in cancer. GATAD2A has been shown to be involved in the regulation of several cancer-related processes, including cancer cell growth, angiogenesis, and drug resistance.
In addition to its role in cancer, GATAD2A has also been shown to be involved in the regulation of fibrosis, a process that involves the replacement of normal tissue with scar tissue. GATAD2A has been shown to promote the development of fibroblasts, which are cells that are responsible for the production of collagen, a protein that is involved in the formation of scar tissue.
In addition to its role in fibrosis, GATAD2A has also been shown to be involved in the regulation of inflammation. GATAD2A has been shown to promote the production of pro-inflammatory cytokines and to inhibit the production of anti-inflammatory cytokines. This means that GATAD2A is involved in the regulation of
Protein Name: GATA Zinc Finger Domain Containing 2A
Functions: Transcriptional repressor (PubMed:12183469, PubMed:16415179). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). Enhances MBD2-mediated repression (PubMed:12183469, PubMed:16415179). Efficient repression requires the presence of GATAD2B (PubMed:16415179)
The "GATAD2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GATAD2A comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GATAD2B | GATB | GATC | GATD1 | GATD1-DT | GATD3 | GATM | GATOR1 Complex | GAU1 | GBA1 | GBA2 | GBA3 | GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1 | GDNF | GDNF Family Receptor alpha | GDNF-AS1 | GDPD1 | GDPD2 | GDPD3 | GDPD4 | GDPD5 | GDPGP1 | GEM | GEMIN2 | GEMIN4 | GEMIN5 | GEMIN6 | GEMIN7 | GEMIN8 | GEMIN8P1 | GEMIN8P4 | GEN1 | general transcription factor IIF (TFIIF) | General transcription factor IIH | Geranylgeranyl transferase | Geranylgeranyl transferase type-1
